Skip to content
ES
MARKETS / NASDAQ / CUPR
NASDAQ · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES

Cuprina Holdings (Cayman) Ltd. CUPR

4 fiscal years on record · SGD · FY2025 reported · SEC filings only
SGD 49,894
▲ 3.3% YoY
SGD -4.7M
SGD -9.2M
In brief

What this company does

As of December 31, 2025, we manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement. We have been selling our MEDIFLY products primarily in Singapore since February 2020. In March 2023, our MEDIFLY products became commercially available in Hong Kong. For our cosmeceuticals business, we introduced three products in 2023, including a hydrating balm product, a muscle energy cream and a pain relief muscle patch.

Written from the business description in Cuprina Holdings (Cayman) Limited's annual report to the U.S. Securities and Exchange Commission, filed 27 April 2026. Every sentence was checked against that document before publication.

Growth
SGD 49,894.00
Revenue, FY2025 · full 4-year series below
Revenue SGD M Net income SGD M
FY2025 · Revenue 0.0 · Net income -4.7
-2M-4M2022202320242025
Compound annual growth
−4.1%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−9367 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -9680.2% · Net -9366.8%
-5000%2022202320242025
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Gross margin-1.3%
Operating margin-9680.2%
Net margin-9366.8%
Return on assets-91.2%
EBITDASGD -4.8M

Each SGD of equity lost 1569 cents this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow SGD M
FY2025 · FCF -9.2
-4M-8M2022202320242025
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsSGD 8.5M
EquitySGD 5.1M
CashSGD 3.1M
Gross debtSGD 164,929.00
Net debtSGD -3.0M
Current ratio2.35×

The company holds more cash than debt.

The 4-year record
4 fiscal years
Every figure from documents filed with the SEC · SGD
row low → row highnegative
Metric 2025202420232022
Revenue SGD B0.00.00.00.0
Operating income SGD B−0.0−0.0−0.0−0.0
EBITDA SGD B−0.0−0.0−0.0−0.0
Income tax SGD B····
Net income SGD B−0.0−0.0−0.0−0.0
Free cash flow SGD B−0.0−0.0−0.0−0.0
EPS, diluted SGD −22.83−8.68−6.22−6.08
Dividend / sh SGD ····
Payout %····
ROE %−1569.1···

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Cuprina Holdings (Cayman) Ltd.vsPhaos Technology Holdings (cayman) Ltd.Same industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Provenance
Company facts, as filed
How we verify · 4 failures in 18 reconciliationsAUDITED

No fiscal year had a computed check that closed clean. 77 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente4 failures
ActivityOrthopedic, Prosthetic & Surgical Appliances & Supplies
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2022

Share this section

Download image